Hotchkis & Wiley Capital Management
HALO icon

Hotchkis & Wiley Capital Management’s Halozyme HALO Stock Holding History

Hotchkis & Wiley Capital Management’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-141,148
Closed -$9.5M – 490
2025
Q4 		$9.5M Buy
141,148
+6,518
+5% +$438K 0.03% 254
2025
Q3 		$9.87M Buy
+134,630
New +$8.94M 0.03% 242

Other funds holding HALO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hotchkis & Wiley Capital Management's HALO Position: Q1 2026 in Review

Hotchkis & Wiley Capital Management sold out of Halozyme (HALO) in Q1 2026, closing a stake of 141,148 shares — an estimated $9.5M sold.

Hotchkis & Wiley Capital Management first reported a position in HALO in Q3 2025 and held it in 2 quarters. The position peaked at $9.87M in Q3 2025. 637 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • Hotchkis & Wiley Capital Management reported no remaining Halozyme position as of Q1 2026 after selling out during the quarter.
  • Hotchkis & Wiley Capital Management sold 141,148 Halozyme shares in Q1 2026, an estimated $9.5M.
  • Hotchkis & Wiley Capital Management first reported a position in Halozyme in Q3 2025 and held it in 2 quarters.
  • Hotchkis & Wiley Capital Management's Halozyme position peaked at $9.87M in Q3 2025.
  • 637 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Hotchkis & Wiley Capital Management's 13F filing for Q1 2026, filed 15 May 2026.